News & Updates

First-line treatment with tumour necrosis factor-α (TNF-α) blockers is both safe and effective in children with inflammatory bowel disease (IBD), according to a recent study. Early drug initiation even cuts the likelihood of treatment failure and leads to fewer extraintestinal symptoms.

Coinfection with hepatitis B virus (HBV) among patients with tuberculosis (TB) appears to be 38-percent to 450-percent more prevalent than published estimates from the Polaris group of region-specific overall HBV prevalence, suggest the results of a meta-analysis.

Researchers at the Chinese University of Hong Kong (CUHK) have rolled out the city’s first territory-wide study of long COVID to inform multidisciplinary follow-up care for thousands of COVID-19 survivors. Participants are also invited to a second-phase 3-year prospective study of the impact of gut dysbiosis on long COVID symptoms and the potential role of gut microbiome modulation in treatment of long COVID.

A recent study has shown that it is possible to implement pre-emptive pharmacogenetic testing into a community-based oncology clinic with results interpretation available for colorectal cancer patients before their scheduled initiation of chemotherapy.

Fathers’ exposure to anti-inflammatory or immunosuppressive medications for inflammatory bowel disease (IBD) prior to conception does not appear to contribute to a significantly increased risk of childhood infections, a study has found.

In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.